← Companies
Amylyx Pharmaceuticals, Inc.
Data as of Oct 16, 2026
AMLX
CIK 1658551Reported federal lobbying
$280K
10 filings · latest Jul 16, 2026
Federal contracts since 2024
$401K
4 awards · latest Mar 25, 2024
Lobbying
$280,000 in reported federal lobbying spend across 10 quarterly filings, most recently Jul 16, 2026. Amounts are the sums companies and their registrants report on Lobbying Disclosure Act filings; a filing that covers several issues counts its full amount under each.
Spend by issue
- Health Issues +1$280K7 filings
Latest filings, Jul 2025 onward
| Filed | Registrant and subject | Amount |
|---|---|---|
| Jul 16, 2026 | TARPLIN, DOWNS & YOUNG, LLC for AMYLYX PHARMACEUTICALS Health Issues · Medicare/Medicaid rare disease and access to innovation
rare disease and access to innovation | $40,000 |
| Apr 20, 2026 | TARPLIN, DOWNS & YOUNG, LLC for AMYLYX PHARMACEUTICALS Health Issues · Medicare/Medicaid rare disease and access to innovation
rare disease and access to innovation | $40,000 |
| Jan 20, 2026 | TARPLIN, DOWNS & YOUNG, LLC for AMYLYX PHARMACEUTICALS Health Issues · Medicare/Medicaid rare disease and access to innovation
rare disease and access to innovation | $40,000 |
| Oct 16, 2025 | TARPLIN, DOWNS & YOUNG, LLC for AMYLYX PHARMACEUTICALS Health Issues · Medicare/Medicaid rare disease and access to innovation
rare disease and access to innovation | $40,000 |
| Sep 22, 2025 | FOLEY HOAG LLP for AMYLYX PHARMACEUTICALS INC. Unspecified | $0 |
| Jul 16, 2025 | TARPLIN, DOWNS & YOUNG, LLC for AMYLYX PHARMACEUTICALS Health Issues · Medicare/Medicaid rare disease and access to innovation
rare disease and access to innovation | $40,000 |